JOHNSON & JOHNSON JNJ 69.32
Health Care · NYSE · Data as of 2026-10-21
JOHNSON & JOHNSON (JNJ) has delivered +2.2% annualized revenue growth, +17.1% earnings growth, and +4.2% dividend growth over 10 years of data. Ranked #284 of 1968 stocks overall and #30 of 260 in the Health Care sector by Steady Score.
About JOHNSON & JOHNSON
Company Overview
Johnson & Johnson develops medicines and medical technologies through Innovative Medicine and MedTech businesses. Its medicines treat cancer, immune disorders, neurological and cardiovascular diseases, while MedTech supplies surgical systems, orthopedics, contact lenses and cardiovascular devices. Hospitals, physicians, pharmacies and patients use these products worldwide, with payment supported by insurers, governments and healthcare institutions.
Read more
Business Model & Revenue
Revenue comes from patented pharmaceuticals, implants, surgical products, devices and vision-care products. Prescription volume, procedures, pricing, reimbursement and new approvals drive sales. Medicines face patent expiration and generic competition, while devices depend on hospital budgets and physician adoption. The company funds extensive research, clinical trials and acquisitions and operates regulated manufacturing and distribution networks across global markets.
Key Facts & Market Position
The 2023 separation of Kenvue removed consumer health, leaving J&J concentrated on prescription medicines and medical technology. Its scale spans laboratory research, clinical evidence, physician training and global commercialization. Product liability, quality compliance and pricing policy are material risks, while portfolio breadth reduces reliance on any single therapeutic area.